120
Participants
Start Date
October 29, 2024
Primary Completion Date
December 31, 2026
Study Completion Date
January 31, 2028
Mosliciguat
Dose level 1, 2, or 3 for inhalation
Dry Powder Inhaler
Dry powder inhaler for mosliciguat or placebo delivery
Placebo
Matching placebo for inhalation
RECRUITING
Lewis Katz School of Medicine, Philadelphia
RECRUITING
PulmonIx, Greensboro
RECRUITING
Duke University Health System - Duke Clinic, Durham
RECRUITING
Medical University of South Carolina, Charleston
RECRUITING
Florida Lung, Asthma & Sleep Specialists/Clinical Research Specialists, LLC, Celebration
RECRUITING
Norton Pulmonary Specialists, Louisville
RECRUITING
Hoxworth Blood Center, Cincinnati
RECRUITING
University of Iowa Hospitals and Clinics, Iowa City
RECRUITING
Northwestern University, Chicago
RECRUITING
University of Kansas Medical Center, Kansas City
RECRUITING
Houston Methodist Lung Center, Houston
RECRUITING
Arizona Pulmonary Specialists, Phoenix
RECRUITING
Ronald Reagan UCLA Medical Center, Los Angeles
RECRUITING
Harbor-UCLA Medical Center - Torrance, Torrance
RECRUITING
University of California Davis School of Medicine, Sacramento
RECRUITING
Summit Health, Bend
RECRUITING
Brown Medicine, East Providence
RECRUITING
University of Utah Health, Salt Lake City
Pulmovant, Inc.
INDUSTRY